Revenues grew 13.1%, including 6.8% organic growth driven by broad-based adoption of our clinical innovations, contributions ...

Good morning, everyone, and thank you for joining us to discuss our third quarter results. Despite the more challenging ...

This transaction strengthens our portfolio, cementing a third high-return foundational asset, diversing our production base ...

Second, Aero 3 expands VSE's global MRO footprint and capabilities with the addition of 9 wheel and brake repair and overhaul ...

Before we begin, I'd like to remind you that our comments and responses to your questions today reflect management's views as ...

The use of IL-1 alpha and beta inhibition with ARCALYST has increasingly become the preferred treatment for recurrent ...

Sir Keir Starmer is facing backbench anger after ministers abandoned plans to give workers day-one protection against unfair ...

Good day, and thank you for joining us. Yesterday, we issued a press release relating to the Phase III HARMONi-6 data ...

Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Third Quarter 2025 Earnings Call. With me today are ...

Despite posting healthy earnings, FoundPac Group Berhad's ( KLSE:FPGROUP ) stock has been quite weak. We have done ...

There is nothing new to report regarding our patent litigation with Teva Pharmaceuticals. Recall that in March 2018, we sued ...

Before we begin, I would like to remind you that today's comments will include forward-looking statements under federal ...